On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...
Axios Vitals on MSN14d
PBMs made more than $7B marking up specialty generics: FTCThe three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade ...
The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback